$Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer$

Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer

For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria, Australia. A retrospective analysis of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current problems in cancer 2022-04, Vol.46 (2), p.100793-100793, Article 100793
Hauptverfasser:	Jalali, A, Gard, G, Banks, S, Dunn, C, Wong, HL, Wong, R, Lee, M, Gately, L, Loft, M, Shapiro, JD, Kosmider, S, Tie, J, Ananda, S, Yeung, J M, Jennens, R, Lee, B, McKendrick, J, Lim, L, Khattak, A, Gibbs, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Australia Colonic Neoplasms - drug therapy Colorectal cancer Colorectal Neoplasms - pathology Drug Combinations Humans Metastatic Middle Aged Neoplasm Recurrence, Local - drug therapy Pyrrolidines Rectal Neoplasms Retrospective Studies TAS-102 Thymine - therapeutic use Trifluridine - therapeutic use Trifluridine/Tipiracil Uracil - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!